 43 patients are planned to be enrolled. The first 6 patients will receive IPH2201 at a dose of 4 mgkg q2w x 4. Subsequent patients will be treated at a dose of 10 mgkg q2w x 4. Standard loco-regional treatment with surgery followed by adjuvant therapy will be initiated after the last administration of IPH2201. 